- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...

- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

ABBOTT PARK, Ill., April 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading 3 continuous glucose monitoring (CGM) technology, can ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

- Provides broader access to FreeStyle Libre system for residents living with diabetes in Ontario and Quebec - FreeStyle Libre is the first sensor-based glucose monitoring system to be listed in any ...

The US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system for adults and children ages 4 years and older with diabetes. The ...